Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
ILMN

ILMN - Illumina Inc Stock Price, Fair Value and News

$118.89+3.33 (+2.88%)
Delayed

42/100

ILMN

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

42/100

ILMN

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

ILMN Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ILMN Price Action

Last 7 days

-4.6%

Last 30 days

2.2%

Last 90 days

-11.8%

Trailing 12 Months

41.4%

ILMN RSI Chart

ILMN Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ILMN Valuation

Market Cap

18.2B

Price/Earnings (Trailing)

21.39

Price/Sales (Trailing)

4.19

EV/EBITDA

12.11

Price/Free Cashflow

19.53

ILMN Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

ILMN Fundamentals

ILMN Revenue

Revenue (TTM)

4.3B

Rev. Growth (Yr)

4.98%

Rev. Growth (Qtr)

6.92%

ILMN Earnings

Earnings (TTM)

850.0M

Earnings Growth (Yr)

79.57%

Earnings Growth (Qtr)

122.67%

ILMN Profitability

Operating Margin

66.08%

EBT Margin

24.99%

Return on Equity

31.22%

Return on Assets

12.79%

Free Cashflow Yield

5.12%

ILMN Investor Care

Buy Backs (1Y)

3.47%

Diluted EPS (TTM)

5.45

ILMN Alerts

  • 1 major insider buys and 2 major insider sales recently.
  • Big jump in Earnings (Y/Y)

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20254.3B4.3B4.3B4.3B
20244.5B4.4B4.4B4.4B
20234.4B4.5B4.5B4.5B
20224.7B4.7B4.7B4.6B
20213.5B4.0B4.3B4.5B
20203.6B3.4B3.2B3.2B
20193.4B3.4B3.5B3.5B
20182.9B3.1B3.2B3.3B
20172.4B2.5B2.6B2.8B
20162.3B2.3B2.4B2.4B
20152.0B2.1B2.1B2.2B
20141.5B1.6B1.7B1.9B
20131.2B1.3B1.3B1.4B
20121.0B1.0B1.1B1.1B
2011993.1M1.1B1.1B1.1B
Get all data in R, Python etc through our Historical Stock Data APIs

About Illumina Inc

ILMN
Illumina, Inc. develops, manufactures, and markets life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; and whole-genome sequencing kits, which sequence entire genomes of any size and complexity, and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. Further, it provides whole-genome sequencing, genotyping, NIPT, and product support services; and Galleri, a multi-cancer early detection test. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. Further, it markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. Illumina, Inc. was incorporated in 1998 and is headquartered in San Diego, California.
 CEO
 WEBSITEillumina.com
 SECTORHealthcare
 INDUSTRYDiagnostics & Research
 EMPLOYEES11500

Illumina Inc Frequently Asked Questions

ILMN is the stock ticker symbol of Illumina Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Mar 13 2026, market cap of Illumina Inc is 18.18 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Fri Mar 13 2026, ILMN's PE ratio (Price to Earnings) is 21.39 and Price to Sales (PS) ratio is 4.19. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ILMN PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Illumina Inc has provided -0.02 (multiply by 100 for percentage) rate of return.